Evidence map›Paper›PMID 29726096›Full record

ArticlePharmaceutical statistics2018

Design and inference for 3-stage bioequivalence testing with serial sampling data.

Fangrong Yan, Huihong Zhu, Junlin Liu, Liyun Jiang, Xuelin Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical statistics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fangrong YanResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Huihong ZhuResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Junlin LiuResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Liyun JiangResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Xuelin Huang · 2002 to 2026
$23.8M
Comparative Modeling: Informing Breast Cancer Control Practice & PolicyU01CA152958 · NCI · GEORGETOWN UNIVERSITY · PI BERRY, DONALD A, DE KONING, HARRY J · 2010 to 2015
$7.6M
National Social Science of China 16BTJ021NCI NIH HHS P50 CA100632NCI NIH HHS U01 CA152958NCI NIH HHS U54 CA096300
6 · The paper itself

Abstract

A bioequivalence test is to compare bioavailability parameters, such as the maximum observed concentration (C

Indexed as

Research DesignBiological AvailabilityClinical Trials as TopicComputer SimulationHumansPharmaceutical PreparationsPharmacokineticsSample SizeTherapeutic EquivalencyPharmaceutical Preparationsbioequivalence testingsample size estimationsequential designserial sampling datastatistical power

Identifiers

PMID29726096
PMCPMC6146059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.